Meeting Banner
Abstract #1124

ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy

Eva-Maria Ratai1,2, Zheng Zhang3, James Fink4, Mark Muzi4, Lucy Hanna3, Erin Greco3, Todd Richards4, Akiva Mintz5, Lale Kostakoglu6, Edward Eikman7, Melissa Prah8, Benjamin Ellingson9, Kathleen Schmainda8, Gregory Sorensen1,2, Daniel Barboriak10, David Mankoff11, and Elizabeth Gerstner12

1Radiology, Massachusetts General Hospital, Boston, MA, United States, 2A. A. Martinos Center for Biomedical Imaging, Charlestown, MA, United States, 3Brown University, Providence, RI, United States, 4University of Washington, Seattle, WA, United States, 5Wake Forest University, Winston-Salem, NC, United States, 6Mt. Sinai Medical Center, New York, NY, United States, 7Moffitt Cancer Center, Tampa, FL, United States, 8Medical College of Wisconsin, Milwaukee, WI, United States, 9UCLA Medical Center, Los Angeles, CA, United States, 10Duke University, Durham, NC, United States, 11University of Pennsylvania, Philadelphia, PA, United States, 12MGH Cancer Center, Massachusetts General Hospital, Boston, MA, United States

The Phase II multi-center trial ACRIN 6684 conducted by the American College of Radiology Imaging Network was designed to assess tumor hypoxia in newly diagnosed glioblastoma (GBM) using [18F] Fluoromisonidazole (FMISO)-PET and MRI. Data from magnetic resonance spectroscopic imaging (MRSI) were available on 17 participants from four sites. The MRS marker of tumor burden (NAA/Cho) was a significant predictor of one-year survival (OS-1). Furthermore, the MRS marker of tumor hypoxia (Lac/Cr) was a significant predictor of six-month progression-free-survival (PFS-6) using receiver operating characteristic (ROC) analysis.

This abstract and the presentation materials are available to members only; a login is required.

Join Here